YouTube video by SHINY COLORS - Topic

YouTube video by シャイニーカラーズ - Topic

YouTube video by シャイニーカラーズ - Topic

YouTube video by Jon B

YouTube video by vhsoundmania

60 Degrees Pharmaceuticals (NASDAQ: SXTP) submitted a New Dietary Ingredient Notification (NDIN) to the FDA on March 11, 2026, for an Australian Chestnut Extract product; FDA review runs through May 25, 2026.The company also signed an option to license Florida State University capsule formulation methods and previously exercised a January 2026 license option for large-scale purification rights for castanospermine.

YouTube video by ZAQ Official Channel

Using AI to find stock market opportunities. Click to read StockQuakes, by StockQuakes Team, a Substack publication with hundreds of subscribers.

Management will meet institutional investors Sept. 14-16 in New York as the company outlines medicines for vector-borne diseases online.

60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported second quarter 2026 results for the period ended June 30, 2026. Net product revenues were approximately $208 thousand, up about 106% from approximately $101 thousand in the second quarter of 2025. Gross profit on product revenues was approximately $57 thousand, compared with about $51 thousand a year earlier.Operating expenses were approximately $2.33 million, up from about $1.86 million in the prior-year quarter. Net loss attributable to common stockholders was approximately $2.40 million, or $0.90 per share, versus a net loss of about $1.84 million, or $5.01 per share, in the second quarter of 2025.The company develops medicines for vector-borne diseases and markets ARAKODA (tafenoquine) for malaria prevention, with three active clinical trials underway for babesiosis.

60 Degrees Pharmaceuticals (NASDAQ: SXTP) entered into definitive agreements for a private placement of 574,713 shares of common stock (or pre-funded warrants in lieu) plus series A and short-term series B warrants to purchase up to 574,713 shares each, at a purchase price of $1.74 per share and accompanying warrants, priced at-the-market under Nasdaq rules.The series A and B warrants have an exercise price of $1.49 per share, are exercisable upon issuance, with series A expiring five years and series B twenty-four months from the effective date of a resale registration statement. Closing is expected on or about July 31, 2026, subject to customary conditions. Gross proceeds are expected to be approximately $1.0 million before fees and expenses, excluding any warrant exercise proceeds. The securities are being offered in a private placement under Section 4(a)(2) and/or Regulation D, and the company intends to use net proceeds for working capital and general corporate purposes.

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the

FSURF deal gives 60 Degrees Pharma an exclusive option to negotiate a U.S. license for castanospermine in four tick-borne disease fields.

Weiss Ratings reissued their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP – Free Report) in a research report sent to investors on Wednesday,Weiss Ratings reports. SXTP has been the topic of a number of other research reports. HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research […]